Cognitive disorders in patients after COVID-19

P.R. Kamchatnov¹, R.A. Cheremin², L.A. Skipetrova², B.A. Abusueva³, L.I. Pyshkina¹, S.A. Khanmurzayeva³

¹Pirogov Russian National Research Medical University, Moscow

²Center for Speech Disorders and Neurorehabilitation, Moscow

³Dagestan State Medical University, Makhachkala

Nowadays, doctors of all specialties in Russia and worldwide are dealing not only with a new coronavirus infection but also with the COVID-19 comorbidities, the so-called post-covid syndrome (PCS). PCS manifestations are diverse and characterized by symptoms from various body systems, and neurological disorders are particularly important: cognitive disorders, asthenic, vegetative, and anxiety disorders, leading to a decrease in the patients’ life quality and a slowdown in the recovery rate. The most significant neurological disorders are observed in patients over 50 years with initially concomitant cardiovascular pathology. The wide prevalence of PCS, its significant impact on the patients’ life requires the search for adequate therapeutic methods. Of undoubted interest is the use of peptide preparations with neuroprotective and neuropreparative effects. The authors present their data f rom the first experience of using the domestic drug, Cellex (pig brain polypeptides), to treat patients with small vessel disease and PCS with cognitive disorder. Therapy positive effect was noted as a decrease in the severity of cognitive disorder, anxiety and asthenic syndromes. Adding that, there was a good tolerability and the absence of severe side effects.

Keywords: COVID-19, post-covid syndrome, cognitive impairment, asthenic syndrome, small vessel disease, chronic cerebral ischemia, treatment.

For citation: Kamchatnov P.R., Cheremin R.A., Skipetrova L.A. et al. Cognitive disorders in patients after COVID-19. RMJ. 2022;4:33–37.